Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
added, America, benchmarking, contemplate, cytotoxicity, dose, doubt, factor, force, Immunotherapy, induced, Issuer, outcome, potency, realizable, realization, satisfaction, settlement, showed, SITC, Society, timeline, tolerated, toxicology, tumor, unfavorable, Unregistered, unsuccessful, xenograft
Removed:
account, borrowing, discount, ELONA, initiated, Phase
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view